Lea Braun, Christoph Löser, Mindaugas Andrulis, Matthias Uhl, Manfred Wolter, Edgar Dippel
{"title":"[病灶内美罗华治疗难治性面部肉芽肿]。","authors":"Lea Braun, Christoph Löser, Mindaugas Andrulis, Matthias Uhl, Manfred Wolter, Edgar Dippel","doi":"10.1007/s00105-025-05476-2","DOIUrl":null,"url":null,"abstract":"<p><p>A 60-year-old man presented with refractory granuloma faciale. After unsuccessful treatment with dapsone, hydroxychloroquine, and radiotherapy, treatment with intralesional rituximab was initiated. This led to a steady improvement in the lesions without serious side effects. The case shows that rituximab can be a treatment option for refractory cases of granuloma faciale, especially in the context of IgG 4-related autoimmune disease.</p>","PeriodicalId":72786,"journal":{"name":"Dermatologie (Heidelberg, Germany)","volume":" ","pages":"220-222"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Intralesional rituximab for refractory granuloma faciale].\",\"authors\":\"Lea Braun, Christoph Löser, Mindaugas Andrulis, Matthias Uhl, Manfred Wolter, Edgar Dippel\",\"doi\":\"10.1007/s00105-025-05476-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A 60-year-old man presented with refractory granuloma faciale. After unsuccessful treatment with dapsone, hydroxychloroquine, and radiotherapy, treatment with intralesional rituximab was initiated. This led to a steady improvement in the lesions without serious side effects. The case shows that rituximab can be a treatment option for refractory cases of granuloma faciale, especially in the context of IgG 4-related autoimmune disease.</p>\",\"PeriodicalId\":72786,\"journal\":{\"name\":\"Dermatologie (Heidelberg, Germany)\",\"volume\":\" \",\"pages\":\"220-222\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatologie (Heidelberg, Germany)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s00105-025-05476-2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologie (Heidelberg, Germany)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00105-025-05476-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/3 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
[Intralesional rituximab for refractory granuloma faciale].
A 60-year-old man presented with refractory granuloma faciale. After unsuccessful treatment with dapsone, hydroxychloroquine, and radiotherapy, treatment with intralesional rituximab was initiated. This led to a steady improvement in the lesions without serious side effects. The case shows that rituximab can be a treatment option for refractory cases of granuloma faciale, especially in the context of IgG 4-related autoimmune disease.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
